Progyny (PGNY) Projected to Post Quarterly Earnings on Thursday

Progyny (NASDAQ:PGNY) is expected to post its Q4 2025 results before the market opens on Thursday, February 26th. Analysts expect Progyny to post earnings of $0.38 per share for the quarter. Individuals may visit the the company’s upcoming Q4 2025 earning results page for the latest details on the call scheduled for Thursday, February 26, 2026 at 4:45 PM ET.

Progyny Stock Performance

Shares of PGNY stock opened at $21.31 on Tuesday. Progyny has a fifty-two week low of $17.98 and a fifty-two week high of $28.75. The firm has a market capitalization of $1.84 billion, a PE ratio of 33.83, a P/E/G ratio of 1.33 and a beta of 0.96. The stock’s 50-day simple moving average is $24.36 and its 200-day simple moving average is $23.16.

Institutional Investors Weigh In On Progyny

Hedge funds have recently modified their holdings of the company. Caitong International Asset Management Co. Ltd acquired a new stake in shares of Progyny during the 4th quarter valued at about $25,000. Canada Pension Plan Investment Board purchased a new position in Progyny during the second quarter worth approximately $77,000. Quarry LP grew its holdings in Progyny by 2,004.1% in the third quarter. Quarry LP now owns 3,598 shares of the company’s stock valued at $77,000 after purchasing an additional 3,427 shares during the period. Tower Research Capital LLC TRC increased its position in shares of Progyny by 203.5% in the second quarter. Tower Research Capital LLC TRC now owns 7,021 shares of the company’s stock valued at $154,000 after buying an additional 4,708 shares in the last quarter. Finally, Entropy Technologies LP purchased a new stake in shares of Progyny in the fourth quarter valued at approximately $203,000. 94.93% of the stock is owned by hedge funds and other institutional investors.

Wall Street Analyst Weigh In

Several equities analysts recently weighed in on PGNY shares. JPMorgan Chase & Co. set a $35.00 price target on shares of Progyny in a report on Wednesday, January 21st. Canaccord Genuity Group upped their price objective on shares of Progyny from $23.00 to $26.00 and gave the company a “hold” rating in a report on Monday, November 17th. Barclays started coverage on shares of Progyny in a report on Monday, December 8th. They set an “overweight” rating and a $29.00 target price for the company. Citigroup upgraded shares of Progyny to an “outperform” rating in a research report on Tuesday, January 20th. Finally, Zacks Research downgraded Progyny from a “strong-buy” rating to a “hold” rating in a research report on Friday, January 30th. Eight equities research analysts have rated the stock with a Buy rating and four have assigned a Hold rating to the company. Based on data from MarketBeat, Progyny presently has an average rating of “Moderate Buy” and a consensus price target of $29.80.

About Progyny

Progyny, Inc is a New York-based fertility benefits management company that partners with employers and health plans to design and administer comprehensive family-building programs. The company’s digital health platform integrates clinical expertise, patient support tools and data analytics to help members navigate fertility treatments, from in vitro fertilization (IVF) and egg freezing to surrogacy and adoption. By focusing on outcomes-based care, Progyny aims to improve success rates while controlling costs for its clients.

The core of Progyny’s offering is its proprietary Smart Cycle® benefit, which bundles clinical, emotional and logistical support into a single package.